Glaukos Corporation (GKOS): Price and Financial Metrics
GKOS Price/Volume Stats
| Current price | $95.13 | 52-week high | $102.33 |
| Prev. close | $96.89 | 52-week low | $45.38 |
| Day low | $94.14 | Volume | 381,950 |
| Day high | $97.29 | Avg. volume | 674,611 |
| 50-day MA | $91.94 | Dividend yield | N/A |
| 200-day MA | $78.67 | Market Cap | 4.71B |
GKOS Stock Price Chart Interactive Chart >
Glaukos Corporation (GKOS) Company Bio
Glaukos Corporation develops and commercializes products and procedures designed for the treatment of glaucoma. The company was founded in 1998 and is based in Laguna Hills, California.
Latest GKOS News From Around the Web
Below are the latest news stories about GLAUKOS CORP that investors may wish to consider to help them evaluate GKOS as an investment opportunity.
Glaukos Corp President & COO Joseph Gilliam Sells 25,000 SharesJoseph Gilliam, President & COO of Glaukos Corp (NYSE:GKOS), executed a sale of 25,000 shares in the company on December 21, 2023, according to a SEC Filing. |
Glaukos Announces Participation in the J.P. Morgan Healthcare ConferenceALISO VIEJO, Calif., December 20, 2023--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 5:15 p.m. PT in San Francisco, CA. |
Glaukos' (GKOS) iDose TR Gets FDA Nod for Glaucoma TreatmentThe FDA approval of Glaukos' (GKOS) iDose TR is likely to reshape glaucoma care. A micro-invasive breakthrough promises proactive, durable treatment, heralding a new era in eye health. |
Glaukos (GKOS) Hits 52-Week High: What's Aiding the Stock?Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent. |
Glaukos wins FDA approval for drug-releasing eye implant to treat glaucomaWilliam Blair analysts said the product “should revolutionize how glaucoma is treated by addressing noncompliance with drops.” |
GKOS Price Returns
| 1-mo | 8.57% |
| 3-mo | 4.21% |
| 6-mo | 40.33% |
| 1-year | 91.83% |
| 3-year | 13.24% |
| 5-year | 36.98% |
| YTD | 19.68% |
| 2023 | 81.98% |
| 2022 | -1.71% |
| 2021 | -40.95% |
| 2020 | 38.17% |
| 2019 | -3.03% |
Continue Researching GKOS
Want to do more research on GLAUKOS Corp's stock and its price? Try the links below:GLAUKOS Corp (GKOS) Stock Price | Nasdaq
GLAUKOS Corp (GKOS) Stock Quote, History and News - Yahoo Finance
GLAUKOS Corp (GKOS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...